Professional Documents
Culture Documents
All 73 1383
All 73 1383
DOI: 10.1111/all.13405
REVIEW ARTICLE
Correspondence
Anthony Dubois, University Medical Centre Abstract
Groningen, Groningen, The Netherlands. Quantitative risk assessment (QRA) for food allergens has made considerable pro-
Email: publications@ilsieurope.be
gress in recent years, yet acceptability of its outcomes remains stymied because of
Funding information the limited extent to which it has been possible to incorporate severity as a variable.
This work was conducted by an expert
group of the European branch of the Reaction severity, particularly following accidental exposure, depends on multiple
International Life Sciences Institute, ILSI factors, related to the allergen, the host and any treatments, which might be admin-
Europe. This publication was coordinated by
the Food Allergy Task Force. Industry istered. Some of these factors are plausibly still unknown. Quantitative risk assess-
members of this task force are listed on the ment shows that limiting exposure through control of dose reduces the rates of
ILSI Europe website at http://ilsi.eu/task-
forces/food-safety/food-allergy/. Experts are reactions in allergic populations, but its impact on the relative frequency of severe
not paid for the time spent on this work; reactions at different doses is unclear. Food challenge studies suggest that the
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2018 The Authors. Allergy Published by John Wiley & Sons Ltd.
Abbreviations: DBPCFC, double-blind, placebo-controlled food challenge; ED, eliciting dose; IgE, Immunoglobulin E; ISO, International Organization for Standardization; MED, minimum
eliciting dose; PAL, precautionary allergen labelling; QRA, quantitative risk assessment; sIgE, specific immunoglobulin E; VITAL, Voluntary Incidental Trace Allergen Labelling; WHO-IPCS,
World Health Organization-International Programme for Chemical Safety.
common causes of fatal food-induced anaphylaxis in the UK, medication and alcohol can impact upon severity, as reviewed
the USA and Australia.18-20 In contrast, soya appears less elsewhere.3,25,26 Some individuals are also able to compensate
18
likely to trigger severe reactions. The food matrix in which physiologically for an allergic reaction, to the extent of recov-
the allergen is presented can affect severity: high fat (eg ering spontaneously from food-induced anaphylaxis.27 All these
chocolate) and heavily spiced foods may affect the kinetics of complicate evaluation of the relationship between dose and
allergen bioavailability, potentially delaying symptom onset, severity.
minimizing initial mild oral symptoms and by confounding • Factors affecting reaction outcome: Severity, and the subse-
“early warning signs” failing to limit the amount of allergen quent outcome, depend not only on the nature of the reaction,
consumed.21,22 Heat-processing can alter the structure of pro- but any subsequent intervention to control the reaction. Delays
teins and therefore their recognition by specific immunoglobu- in seeking medical attention and/or administration of adrenaline
lin E (sIgE) and, ultimately, the nature of any reaction.23 The (epinephrine) are common factors reported in fatal anaphylaxis.
relationship between dose (exposure) and reaction severity is Many severe reactions can have a good outcome if appropri-
less clear (see next section), although some (but not all) data ately treated with epinephrine. Contact or inhaled exposures
suggest that severe reactions to very low doses are uncom- are less likely to trigger severe reactions. If dose affects the
mon.24 rate of symptom progression, then a higher dose might limit
• Host factors: These include factors which might affect the the time available to administer rescue medication. The ultimate
ability of an allergen to stimulate a host effector cell response outcome of an allergic reaction expressed as a severity score
(ie an allergic reaction) as well as factors which may modulate will thus require great care to integrate into a QRA. Smith
the response. Perhaps the most studied factor is the level of et al28 proposed the “Swiss cheese” model to illustrate how
allergen-specific IgE, which, however, shows a poor correlation these factors might interact to result in reactions of different
with reaction severity (either historical, or that occurring at in- severity. Essentially, this approach postulates that a severe reac-
hospital food challenge), as do “components” or IgE against tion results from alignment of a whole set of circumstances,
specific epitopes.3 “Extrinsic” factors (also referred to as of which ingested dose is only one factor, as illustrated in
cofactors or augmentation factors) such as exercise, stress, Figure 2.
1388 | DUBOIS ET AL.
Summary Section 4 quantity and bioavailability of the allergen ingested (precisely the vari-
minimize the risk and limit reaction severity include (in some studies) of severe symptoms to peanut, hazelnut, celery, fish and shrimp at
the exclusion of patients with recent severe reactions or severe and/ lower doses, and more frequent severe symptoms as doses increased.
or unstable comorbidities; conducting challenges under baseline con- This is in contrast to Rolinck-Werninghaus et al38 who, using an initial
ditions; and prompt and optimal treatment of reactions. It has been dose of 3-5 mg protein (approximately an ED10 for the allergens
suggested that giving incremental doses in succession may affect the tested), reported severe reactions at all doses. The higher starting dose
impact of subsequent doses, by inducing short-term oral tolerance; may have obscured the relationship between dose and severity.
this would underestimate the effect of any given dose, relative to A recent re-analysis of challenge data by Wainstein & Turner,40
35
the same dose given in isolation. Conversely, reactions may be in which dose escalation continued despite the occurrence of mild
triggered by the cumulative dose, rather than that given immediately symptoms, reported three patterns of reaction: those whose first
prior to reaction: confounding any attempt to relate severity to symptom was anaphylaxis, a group with milder symptoms progress-
dose.36 Finally, even reactions seen at food challenge are open to ing to anaphylaxis as the dose increased or treatment was delayed,
37
considerable inter- and intra-observer variability. and finally a group who did not progress to anaphylaxis irrespective
Analyses examining the relationship between MED and reaction of dose (see Figure 3). This suggests that a relationship between
severity report that relatively severe reactions occur unpredictably dose and severity will not be readily apparent in individuals who
and at any dose.37,38 In order to quantify the effect of ED on reac- react with anaphylaxis as the initial objective symptom, depending
tion severity, Pettersson et al (manuscript in preparation) analysed on starting dose. At a group or population level, the relationship
data arising from 734 positive challenges at a single centre, using between dose and reaction severity may thus be obscured by the
multiple regression analysis to build a prediction model for challenge heterogeneity of the tested allergic population.
reaction severity. This analysis showed that MED could only predict
4.4% of the variance of reaction severity (and all known factors
5.3 | Single-dose challenges
together, only 23.5% of total severity variance).
Zhu et al39 retrospectively classified the severity of MEDs from Zurzolo et al29 introduced single-dose challenges to validate the EDs
graded food challenges performed at several centres and modelled calculated from population dose-distribution curves: a single dose
their distribution in the study population. For peanut, higher MEDs (corresponding to a specific ED value, for example ED05 for the
were associated with more severe reactions, but no clear relation- food in question, derived from a dose distribution curve) is given to
ship was discerned for milk, egg or soy. Importantly, Zhu et al were unselected individuals with the relevant allergy and the occurrence
unable to obtain and therefore include MEDs associated with mild and characteristics of any reactions recorded. In the only study pub-
symptoms in their analysis: these constituted over 40% of the MEDs lished to date, the ED05 for peanut was validated (1.5 mg peanut
39
in the source studies. protein), with 8 of 378 individuals meeting predetermined criteria for
Not all data from food challenges suggest that severe reactions a positive, objective reaction. No severe reactions occurred.16 Addi-
occur at any dose. Ballmer-Weber et al 24
using a challenge protocol tional “single-dose” data can be found by studying historical food
where the initial dose was 0.003 mg protein, observed a clear absence challenge studies, where much higher starting doses were used. Two
F I G U R E 3 Different patterns of clinical reactivity are seen at food challenge. Many individuals will experience initially subjective symptoms,
with objective symptoms appearing with further doses (A). Anaphylaxis will only develop if the food challenge continues. Others will
experience anaphylaxis as their first objective symptom: either at a dose of allergen exposure with no preceding subjective symptoms (B), or
with prior subjective symptoms (C). Note that anaphylaxis can occur at all levels of exposure (both at low levels of allergen exposure,
represented by the solid bars, and higher doses indicated by dotted lines). Reproduced (with permission) from reference40
1390 | DUBOIS ET AL.
such studies (where initial doses were >200 mg protein) had a high studies, which include severity information (eg16,24,38,41,42). Any esti-
proportion (up to 30%) of severe symptoms among first dose reac- mate for proportion of severe reactions would need to be calculated
tors.41,42 These imply that a quantifiable relationship does exist for each allergen (where sufficient data are available). Additional vari-
between severity and dose. However, the circumstances leading to ables that modify severity (ie cofactors) could ultimately be added to
relatively severe reactions at relatively low doses (3-5 mg protein) in the QRA framework as more data become available.
regular (multiple dose) food challenges remain unclear,38 and further
Summary Section 6
data from single-dose challenges are needed before definitive con-
clusions can be drawn. Again it must be stressed that the doses in • Probabilistic risk models may be improved if a quantitative
38 expression of severity could be extracted from clinical data;
the Rolinck-Werninghaus study are at least 1.5 orders of magni-
tude higher than any amounts to which industry is seeking to man- • It may be necessary to generate new data (such as those from
age the allergens tested. single-dose challenges) in order to reliably identify the effect of
dose on severity for use in QRA.
Summary Section 5
cross-contact) in an small amount not exceeding in total the dose 4. Kroes R, Galli C, Munro I, et al. Threshold of toxicological concern
tested. for chemical substances present in the diet: a practical tool for
assessing the need for toxicity testing. Food Chem Toxicol.
Developing a shared understanding among stakeholders of sever-
2000;38:255-312.
ity, and its implications for allergen risk assessment, may be as 5. Food and Agriculture Organization of the United Nations, World
important to the latter’s more general acceptance as refining the Health Organization. Principles and methods for the risk assessment
underlying science. Communicating the issues discussed and conclu- of chemicals in food. 2009.
6. Crevel RWR, Baumert JL, Baka A, et al. Development and evolution
sions reached in this paper to healthcare professionals and people
of risk assessment for food allergens. Food Chem Toxicol.
with food allergies will be critical to developing this understanding, 2014;67:262-276.
and the expert group recognized the associated difficulties. Further 7. Eastmond DA, Hartwig A, Anderson D, et al. Mutagenicity testing
research into conveying risk messages through labelling is also for chemical risk assessment: update of the WHO/IPCS Harmonized
Scheme. Mutagenesis. 2009;24:341-349.
needed to ensure better understanding and therefore protection of
8. Crevel RWR, Briggs D, Hefle SL, Knulst AC, Taylor SL. Hazard char-
allergic consumers. acterisation in food allergen risk assessment: the application of sta-
tistical approaches and the use of clinical data. Food Chem Toxicol.
2007;45:691-701.
ACKNOWLEDGMENTS 9. Taylor SL, Crevel RWR, Sheffield D, Kabourek J, Baumert J. Thresh-
old dose for peanut: risk characterization based upon published
The authors wish to thank Professor Katie Allen (Murdoch Chil-
results from challenges of peanut-allergic individuals. Food Chem Tox-
dren’s Research Institute, AU) for critically reviewing the draft icol. 2009;47:1198-1204.
manuscript. Furthermore, the authors warmly thank all participants 10. Taylor SL, Baumert JL, Kruizinga AG, et al. Establishment of refer-
of the workshop on “How Far Can We Control the Severity of ence doses for residues of allergenic foods: report of the VITAL
expert panel. Food Chem Toxicol. 2014;63:9-17.
Food Allergic Reactions by Controlling Exposure to Allergenic
11. Muraro A, Roberts G, Worm M, et al. Anaphylaxis: guidelines from
Foods?” organized by ILSI Europe on 15-16 September 2016 in the European academy of allergy and clinical immunology. Allergy.
Brussels, Belgium. 2014;69:1026-1045.
12. Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the diagno-
sis and management of food allergy in the United States: sum-
CONFLICTS OF INTEREST mary of the NIAID-sponsored expert panel report. Nutr Res.
2011;31:61-75.
All authors have completed the ICMJE Form for Disclosure of Poten-
13. Hourihane JO, Grimshaw KEC, Lewis SA, et al. Does severity of
tial Conflicts of Interest. low-dose, double-blind, placebo-controlled food challenges reflect
severity of allergic reactions to peanut in the community? Clin Exp
Allergy. 2005;35:1227-1233.
AUTHOR CONTRIBUTIONS 14. McBride D, Keil T, Grabenhenrich L, et al. The EuroPrevall birth
cohort study on food allergy: baseline characteristics of 12,000 new-
All authors contributed to the conception and conduct of the
borns and their families from nine European countries. Pediatr Allergy
research described. AD and RC wrote the paper. AD had primary Immunol. 2012;23:230-239.
responsibility for final content. All authors critically read, commented 15. Sampson HA, Van Wijk RG, Bindslev-Jensen C, et al. Standardizing
on and approved the final manuscript. double-blind, placebo-controlled oral food challenges: American
Academy of Allergy, Asthma & Immunology-European Academy of
Allergy and Clinical Immunology PRACTALL consensus report. J
Allergy Clin Immunol. 2012;130:1260-1274.
ORCID
16. Hourihane JO, Allen KJ, Shreffler WG, et al. Peanut Allergen Thresh-
A. E. J. Dubois http://orcid.org/0000-0001-7909-0296 old Study (PATS): novel single-dose oral food challenge study to vali-
date eliciting doses in children with peanut allergy. J Allergy Clin
P. J. Turner http://orcid.org/0000-0001-9862-5161
Immunol. 2017;139:1583-1590.
17. Barnett J, Muncer K, Leftwich J, et al. Using’may contain’labelling to
inform food choice: a qualitative study of nut allergic consumers.
REFERENCES BMC Public Health. 2011;11:734.
18. Turner PJ, Gowland MH, Sharma V, et al. Increase in anaphylaxis-
1. The European Parliament and the Council of the European Union. related hospitalizations but no increase in fatalities: an analysis of
Regulation (EU) No 1169/2011 of the European Parliament and of United Kingdom national anaphylaxis data, 1992-2012. J Allergy Clin
the Council of 25 October 2011 on the provision of food informa- Immunol. 2015;135:956-963.
tion to consumers. 2011. https://doi.org/10.3000/19770677.l_2011. 19. Ma L, Danoff TM, Borish L. Case fatality and population mortality
304.eng associated with anaphylaxis in the United States. J Allergy Clin Immu-
2. The European Parliament and the Council of the European Union. nol. 2014;133:1075-1083.
Regulation (EC) No 178/2002 of 28 January 2002 laying down the 20. Mullins RJ, Wainstein BK, Barnes EH, Liew WK, Campbell DE.
general principles and requirements of food law, establishing the Increases in anaphylaxis fatalities in Australia from 1997 to 2013.
European Food Safety Authority and laying down procedures in mat- Clin Exp Allergy. 2016;46:1099-1110.
ters of food safety. 2002. doi:2004R0726 - v.7 of 05.06.2013 21. van Odijk J, Ahlstedt S, Bengtsson U, Borres MP, Hulthen L. Dou-
3. Turner PJ, Baumert JL, Beyer K, et al. Can we identify patients at ble-blind placebo-controlled challenges for peanut allergy the effi-
risk of life-threatening allergic reactions to food? Allergy. ciency of blinding procedures and the allergenic activity of peanut
2016;71:1241-1255. availability in the recipes. Allergy. 2005;60:602-605.
1392 | DUBOIS ET AL.
22. Grimshaw KEC, King RM, Nordlee JA, Hefle SL, Warner JO, Houri- clinical thresholds for peanut allergy. J Allergy Clin Immunol.
hane JOB. Presentation of allergen in different food preparations 2014;134:390-398.
affects the nature of the allergic reaction–a case series. Clin Exp 37. van Erp FC, Knulst AC, Meijer Y, Gabriele C, van der Ent CK. Stan-
Allergy. 2003;33:1581-1585. dardized food challenges are subject to variability in interpretation
23. Nowak-Wegrzyn A, Fiocchi A. Rare, medium, or well done? The of clinical symptoms. Clin Transl Allergy. 2014;4:43.
effect of heating and food matrix on food protein allergenicity. Curr 38. Rolinck-Werninghaus C, Niggemann B, Grabenhenrich L, Wahn U,
Opin Allergy Clin Immunol. 2009;9:234-237. Beyer K. Outcome of oral food challenges in children in relation to
24. Ballmer-Weber BK, Fernandez-Rivas M, Beyer K, et al. How much is symptom-eliciting allergen dose and allergen-specific IgE. Allergy.
too much? Threshold dose distributions for 5 food allergens. J 2012;67:951-957.
Allergy Clin Immunol. 2015;135:964-971. 39. Zhu J, Pouillot R, Kwegyir-Afful EK, Luccioli S, Gendel SM. A retro-
25. Niggemann B, Beyer K. Factors augmenting allergic reactions. Allergy. spective analysis of allergic reaction severities and minimal eliciting
2014;69:1582-1587. doses for peanut, milk, egg, and soy oral food challenges. Food Chem
26. Wolbing F, Biedermann T. Anaphylaxis: opportunities of stratified medi- Toxicol. 2015;80:92-100.
cine for diagnosis and risk assessment. Allergy. 2013;68:1499-1508. 40. Turner PJ, Wainstein BK. Crossing the threshold: can outcome data
27. Noimark L, Wales J, Du Toit G, et al. The use of adrenaline autoin- from food challenges be used to predict risk of anaphylaxis in the
jectors by children and teenagers. Clin Exp Allergy. 2012;42:284-292. community? Allergy. 2017;72:9-12.
28. Smith PK, Hourihane JO, Lieberman P. Risk multipliers for severe 41. Perry TT, Matsui EC, Conover-Walker MK, Wood RA. Risk of oral
food anaphylaxis. World Allergy Organ J. 2015;8:30. food challenges. J Allergy Clin Immunol. 2004;114:1164-1168.
29. Zurzolo GA, Allen KJ, Taylor SL, et al. Peanut Allergen Threshold 42. Sicherer SH, Morrow EH, Sampson HA. Dose-response in double-
Study (PATS): validation of eliciting doses using a novel single-dose blind, placebo-controlled oral food challenges in children with atopic
challenge protocol. Allergy Asthma Clin Immunol. 2013;9:35. dermatitis. J Allergy Clin Immunol. 2000;105:582-586.
30. Bock SA, Mun ~oz-Furlong A, Sampson HA. Fatalities due to anaphy- 43. Spanjersberg MQI, Kruizinga AG, Rennen MAJ, Houben GF. Risk
lactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-193. assessment and food allergy: the probabilistic model applied to aller-
31. Pumphrey RSH, Gowland MH. Further fatal allergic reactions to food gens. Food Chem Toxicol. 2007;45:49-54.
in the United Kingdom, 1999-2006. J Allergy Clin Immunol. 44. Rimbaud L, Heraud F, La Vieille S, Leblanc J-C, Crepet A. Quantita-
2007;119:1018-1019. tive risk assessment relating to adventitious presence of allergens in
32. Umasunthar T, Leonardi-Bee J, Hodes M, et al. Incidence of fatal food: a probabilistic model applied to peanut in chocolate. Risk Anal.
food anaphylaxis in people with food allergy: a systematic review 2010;30:7-19.
and meta-analysis. Clin Exp Allergy. 2013;43:1333-1341.
33. Steensma DP. The kiss of death: a severe allergic reaction to a shell-
fish induced by a good-night kiss. Mayo Clin Proc. 2003;78:221-222.
34. Maloney JM, Chapman MD, Sicherer SH. Peanut allergen exposure How to cite this article: Dubois AEJ, Turner PJ, Hourihane J,
through saliva: assessment and interventions to reduce exposure. J et al. How does dose impact on the severity of food-induced
Allergy Clin Immunol. 2006;118:719-724.
allergic reactions, and can this improve risk assessment for
35. Niggemann B, Lange L, Finger A, Ziegert M, Mu €ller V, Beyer K.
Accurate oral food challenge requires a cumulative dose on a subse- allergenic foods? Allergy. 2018;73:1383–1392.
quent day. J Allergy Clin Immunol. 2012;130:261-263. https://doi.org/10.1111/all.13405
36. Blumchen K, Beder A, Beschorner J, et al. Modified oral food chal-
lenge used with sensitization biomarkers provides more real-life